Shilpa Medicare Ltd. has posted Q2 FY25 consolidated profit at Rs. 18 crore as compared to Rs. 1.6 crore in Q2 FY24, reflecting a growth of 1,008 per cent. Total Revenue in Q2 FY25 stood at Rs. 348.8 crore as compared to Rs. 314.8 crore with a growth of 11 per cent. EBITDA in Q2 FY25 stood at Rs. 91 crore as compared to Rs. 62.1 crore with a growth of 46 per cent.

For H1 FY25, Shilpa Medicare posted PAT of Rs. 32.1 crore as compared to Rs. 2.8 crore in H1 FY24, showing a growth of 1040 per cent. Total Revenue in H1 FY25 stood at Rs. 650.7 crore as compared to Rs. 576.9 crore in H1 FY24, reflecting a growth of 13 per cent.

Commenting on the result, Vishnukant Bhutada, Managing Director, Shilpa Medicare, said: “Our strategic focus on delivering innovative solutions and driving operational excellence continues to yield strong business performance. The recent positive developments in our formulations and CDMO businesses are particularly exciting. The recent acceptance of Oxylanthanum Carbonate NDA by USFDA with target action date in June 25 and the recent USFDA approvals of Bortezomib are significant milestones that validate our commitment to quality, innovation, and patient care. These achievements are a testament to the hard work and dedication of our talented team.

“As we continue to expand our global footprint and diversify our product portfolio, we are well-positioned to deliver sustainable growth and create value for our stakeholders. We remain committed to leveraging our strong R&D capabilities to develop cutting-edge products and solutions that address unmet medical needs. We believe that long term sustainability and growth is a product of focusing on strategic partnerships, operational efficiencies, and a customer-centric approach, which are the core values of our business philosophy.”